Drug-drug interactions: The silent epidemic

Psychiatric Services

Volumn 56, Issue 1, 2005, Pages 22-24

  Sandson, Neil ^a,b  

^a SHEPPARD PRATT HEALTH SYSTEM   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ASTEMIZOLE; BARBITURIC ACID DERIVATIVE; CISAPRIDE; CLARITHROMYCIN; CYTOCHROME P450; CYTOCHROME P450 3A4 INHIBITOR; CYTOCHROME P450 INHIBITOR; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROMYCIN; FLUOXETINE; GLIBENCLAMIDE; GLUCOCORTICOID; ISOSORBIDE; PHENELZINE; PHENYTOIN; POTASSIUM SPARING DIURETIC AGENT; PSYCHOTROPIC AGENT; PYRROLE DERIVATIVE; RIFAMPICIN; SELEGILINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SILDENAFIL; STATIN; SULFONAMIDE; TERFENADINE; TRIHEXYPHENIDYL; UNCLASSIFIED DRUG; WARFARIN;

ARTICLE; CLINICAL MEDICINE; COMPUTER PROGRAM; DELIRIUM; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EXPOSURE; EPIDEMIC; FUTUROLOGY; HEALTH CARE COST; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOGLYCEMIA; HYPOKALEMIA; LD 50; MEDICAL ERROR; PARKINSON DISEASE; POLYPHARMACY; PREVENTIVE HEALTH SERVICE; TORSADE DES POINTES; TOXICITY;

AGE FACTORS; CYTOCHROME P-450 ENZYME SYSTEM; DATABASES, FACTUAL; DRUG INTERACTIONS; DRUG THERAPY; HOSPITALIZATION; HUMANS; MEDICAL ERRORS; P-GLYCOPROTEINS; SOFTWARE;

EID: 11844254455     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ps.56.1.22     Document Type: Article

References (20)

1. Aspden P, Corrigan JM, Wolcott J, et al: Patient Safety: Achieving a New Standard for Care. Institute of Medicine, 2003
2. Sandson, NB: Drug Interactions Casebook: The Cytochrome P450 System and Beyond. Washington DC, American Psychiatric Publishing, 2003
3. Cozza KL, Armstrong SC, Oesterheld JR: Concise Guide to Drug Interaction Principles for Medical Practice: Cytochrome P450s, UGTs, P-Glycoproteins, 2nd ed. Washington DC, American Psychiatric Publishing, 2003
4. Grymonpre RE, Mitenko PA, Sitar DS, et al: Drug-associated hospital admissions in older medical patients. Journal of the American Geriatrics Society 36:1092-1098, 1988
5. Goldberg RM, Mabee J, Chan L, et al: Drug-drug and drug-disease interactions in the ED: analysis of a high-risk population. American Journal of Emergency Medicine 14:447-450, 1996
6. Jankel CA, McMillan JA, Martin BC: Effect of drug interactions on outcomes of patients receiving warfarin or theophylline. American Journal of Hospital Pharmacy 51:661-666, 1994
7. Einarson T, Metge C, Iskedjian M, et al: An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutaryl-coenzyme A reductase inhibitors on health care utilization: a Canadian population-based study. Clinical Therapeutics 24:2126-2136, 2002
8. Juurlink DN, Mamdani M, Kopp A, et al: Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA 289:1652-1658, 2003
9. Glassman P, Simon B, Belperio P, et al: Improving recognition of drug interactions: benefits and barriers to using automated drug alerts. Medical Care 40:1161-1171, 2002
10. Langdorf MI, Fox JC, Marwah RS, et al: Physician versus computer knowledge of potential drug interactions in the emergency department. Academic Emergency Medicine 7:1321-1329, 2000
11. Cavuto NJ, Woosley RL, Sale M: Pharmacies and prevention of potentially fatal drug interactions. JAMA 275:1086-1087, 1996
12. Hamilton RA, Briceland LL, Andritz MH: Frequency of hospitalisation after exposure to known drug-drug interactions in a Medicaid population. Pharmacotherapy 18:1112-1120, 1998
13. Roblin DW, Juhn PI, Preston BJ, et al: A low-cost approach to prospective identification of impending high cost outcomes. Medical Care 37:1155-1163, 1999
14. Alfaro CL: Emerging role of drug interaction studies in drug development: the good, the bad, and the unknown. Psychopharmacology Bulletin 35:80-93, 2001
15. Yap Y, Camm A: Potential Cardiac toxicity of H1-antihistamines. Clinical Allergy and Immunology 17:389-419, 2002
16. Michalets EL, Williams CR: Drug interactions with cisapride: clinical implications. Clinical Pharmacokinetics 39:49-75, 2000
17. Shad MU, Marsh C, Preskorn SH: The economic consequences of a drug-drug interaction. Journal of Clinical Psychopharmacology 21:119-120, 2001
18. Flammini S, Spurr C, Grant K: Where saving money meets saving lives. Health Management Technology 20:40-41, 1999
19. Halkin H, Katzir I, Kurman I, et al: Preventing drug interactions by online prescription screening in community pharmacies and medical practices. Clinical Pharmacology and Therapeutics 69:260-265, 2001
20. Hazlet TK, Lee TA, Hansten PD, et al: Performance of community pharmacy drug interaction software. Journal of the American Pharmaceutical Association 41:200-204, 2001